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Abstract
The aim of this work was to study in rats the nasal route for the brain delivery of the vasoactive intestinal peptide (VIP)
neuropeptide. After evaluating VIP stability in solutions obtained from nasal washes, the effect of formulation parameters
(pH 4–9, 0–1% (w/v) lauroylcarnitine (LC), hypo- or isoosmolality) on the brain uptake of intranasally administered VIP
(10−8 M)/125I-VIP (300,000 cpm/ml) was studied, using an in situ perfusion technique. Brain radioactivity distribution was
assessed by quantitative autoradiographic analysis. Results were compared to intravenously administered VIP. With a hypotonic
formulation at pH 4 containing 0.1% LC and 1% bovine serum albumin, VIP stability was satisfactory and loss by adsorption
was minimal. Using this formulation, around 0.11% of initial radioactivity was found in the brain after 30 min perfusion and
was located in the olfactory bulbs, the midbrain and the cerebellum. HPLC analysis of brain and blood extracts demonstrated
the presence of intact VIP in brain and its complete degradation in the blood compartment. By intravenous administration, no
intact VIP was found either in brain or in blood. In conclusion, intact VIP could be delivered successfully to the brain using the
intranasal route for administration.
© 2003 Elsevier Science B.V. All rights reserved.
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1. Introduction
The brain delivery of large hydrophilic drug
molecules (peptides, proteins) is severely hindered by
the presence of the blood–brain barrier (BBB) which




strictly controls the access of solutes to the brain
(Begley, 1996). Several strategies, such as drug li-
pidization, conjugation to ligands or incorporation in
BBB-targeting liposomes have been proposed to cross
the BBB (Pardridge, 1998). Besides, the intranasal
route offers a much simpler approach for brain drug
delivery (Illum, 2000). The olfactory receptor cells
are in contact with both the nasal cavity and the
central nervous system (CNS) (Uraih and Maronpot,
1990) and this neuronal connection constitutes a
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direct pathway to the brain, the drugs reaching the
brain parenchyma mainly by a paracellular route
(Mathison et al., 1998; Illum, 2000). By intranasal
administration, drugs not only circumvent the BBB,
but they also avoid the hepatic first-pass effect
and/or degradation in the blood compartment, a
particularly important issue in the case of peptide
drugs. Intranasally administered proteins or peptides,
e.g. wheat germ agglutinin-horseradish peroxidase
(Shipley, 1985), nerve growth factor (NGF) (Frey
et al., 1997), and insulin (Gizurarson et al., 1997), were
demonstrated to reach the CNS. A pharmacological
response was evidenced after intranasal administra-
tion of a lipophilic vasoactive intestinal peptide (VIP)
analogue unable to cross the BBB (Gozes et al., 1996).
VIP is a 28-amino acid neuropeptide of the
glucagon-secretin family (Mutt and Said, 1970) with
a widespread distribution in both the central and
peripheral nervous system (Fahrenkrug, 1979). It ex-
erts diverse peripheral biological functions, such as
anti-inflammatory and immunomodulatory effects,
smooth muscle relaxation, regulation of cell growth
and differentiation and participates in the function
and in the development of neural tissue (Muller et al.,
1995). It also plays an important role in the cerebral
metabolism (Magistretti et al., 1981) and is involved
in cerebral carcinogenesis (Lelièvre et al., 1998). VIP
could have interesting applications in the treatment of
various neurological disorders, like Alzheimer’s dis-
ease, and a lipophilic VIP analogue was proposed for
such a therapeutic application (Gozes et al., 1996).
However, like most endogenic peptides, its potential
therapeutic applications are limited by its failure to
cross the BBB (McCulloch and Edvinsson, 1980) and
its rapid elimination after intravenous administration.
Its half-life in vivo in blood was determined to be
less than 1 min in rat (Hassan et al., 1994) and ap-
proximately 1 min in man (Domschke et al., 1978). In
order to solve this problem, liposomal formulations
for intravenous use have been proposed to protect
VIP from degradation (Gao et al., 1994; Gololobov
et al., 1998; Önyüksel et al., 1999). As liposomes
were unable to cross the BBB, the sole pharmacologi-
cal effect obtained was a peripheral vasodilation (Gao
et al., 1994). For brain delivery, a VIP analogue was
conjugated to the OX26 monoclonal murine antibody
directed against the rat transferrin receptor (Bickel
et al., 1993). This conjugation permitted a significant
brain uptake of the analogue administered intra-
venously in rats, associated with a 65% increase in
cerebral blood flow. For the treatment of neurological
disorders, however, systemic administration of VIP
entrapped in liposomes or in the form of long-lasting
analogue should be avoided, in respect to the multiple
biological effects of VIP on peripheral tissues which
could lead to major adverse effects (Verner-Morrison
Syndrome) (Domschke et al., 1978). VIP is therefore
an interesting model to evaluate the potential advan-
tages of the intranasal over the intravenous route for
brain delivery of peptides. One could expect that after
intranasal administration VIP may reach the brain tis-
sue in an intact form via the direct nose-to-brain path-
way, whereas the fraction of VIP that may reach the
blood compartment would be considerably reduced,
thus avoiding potential peripheral adverse effects.
The aim of this study was to investigate the brain
uptake of VIP after nasal administration, including the
effect of some formulation parameters on this uptake
(pH, osmolality and the presence of lauroylcarnitine
(LC) as a permeation enhancer).
2. Experimental
2.1. Chemicals
Human VIP (pI 9.82, Mw 3326.82, calculated
using the ExPASy Proteomics Tools from the
www.expasy.ch/tools website) was obtained from
Neosystem (France). 125I-Na (2200 Ci/mmol) was
provided by NEN DuPont (France). Chloramine T,
d,l-lauroylcarnitine chloride, bovine serum albu-
min (BSA), sodium metabisulfite, trifluoroacetic acid
(TFA) were purchased from Sigma (France).
2.2. Animals
The animal experiments adhered to the Princi-
ples of Laboratory Animal Care (NIH Publication
#86-23, revised 1985). Male Sprague–Dawley rats
(250–300 g) obtained from Déprés Breeding Labo-
ratories (St. Doulchard, France) were housed in the
animal breeding facilities of the laboratory (Autho-
rization No. 0028) for 4–6 days before experiments.
They were maintained in a light- (12-h light–dark
cycle) and temperature-controlled environment with
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free access to water and food. Food was withdrawn
24 h before experiments.
2.3. VIP radiolabelling and purification
VIP was radioiodinated on Tyr10 using the chlo-
ramine T method as previously described (Martin
et al., 1986). Briefly, the reaction was initiated by
addition of 25l of a 3 mg/ml chloramine T solution
(prepared in a 0.2 M sodium phosphate buffer (pH
7.6)) to 15l of a 10−4 M (5g) aqueous solution
of VIP mixed with 5l of 125I-Na solution (around
0.45 mCi). After 1 min, the reaction was stopped
with 25l of a 2 mg/ml sodium metabisulfite pre-
pared in the same buffer. The radioiodination mix
was then passed on a C18 Sep-Pak column (Waters
Associates) using 10 ml of a 0.1% trifluoroacetic acid
(TFA) aqueous solution as eluent in order to discard
free radioiodine. 125I-VIP was then recovered using
2.5 ml of 85:15 acetonitrile:0.1% TFA in water as elu-
ent. It was further purified by reversed-phase HPLC.
The fractions containing the monoiodinated form of
125I-VIP (Tyr10-125I)VIP) were dried under nitrogen
and stored at −20 ◦C.
2.4. Animal experiments
2.4.1. Intranasal administration procedure
The intranasal administration procedure was based
on the in situ nasal multipass perfusion method of
Hirai et al. (1981). Overnight fasted male Sprague–
Dawley rats (250–300 g) were anesthetized by in-
traperitoneal injection of 20% (w/v) ethylurethane
(1 g/kg body weight), which permitted an effective
anesthesia all over the experiment. After incision of
the neck of the rat laying on its back under a heating
lamp, the trachea was cannulated with a polyethylene
tube (i.d. 1.19 mm, e.d. 1.70 mm, no. 8, Polylabo,
France) to aid breathing. Another polyethylene tube
(i.d. 0.86 mm, e.d. 1.52 mm, no. 6) was inserted
through the esophagus toward the posterior part of
the nasal cavity. It was connected to a reservoir of so-
lution (buffers in the case of preliminary VIP stability
experiments or VIP formulations in the case of brain
uptake experiments) at 37 ◦C in a water-bath. The na-
sopalatine tract was sealed using cyanoacrylate glue to
prevent the drainage of solution from the nasal into the
oral cavity. By means of a peristaltic pump (Minipuls
II, Gilson) the solution (1.5 ml) was circulated for
30 min (except when stated differently) from the reser-
voir through the nasal cavity and out of the nostrils
back into the reservoir at a flow rate of 2 ml/min.
2.4.2. Stability of VIP in nasal wash solutions
VIP stability was evaluated in nasal wash solu-
tions using a method adapted from Aungst and Phang
(1995). To prepare the nasal wash solutions, three
hypotonic (20 mOsm/kg) buffered solutions (10 mM
citrate (pH 4) or 10 mM phosphate buffer (pH 7 or
9)) were circulated for 30 min as described above
to collect mucosal secretions. To 330l of these
solutions supplemented with 1% (w/v) BSA were
added VIP (10−8 M final concentration) and 125I-VIP
(300,000 cpm/ml final concentration, 7.5 × 10−11 M)
and the mix (450l) was incubated at 37 ◦C for
30 min. The effect of 0.1% LC (w/v) on VIP stability
was also evaluated. To check for peptide adsorption
onto polyethylene containers, VIP was incubated in
buffered solutions (pH 4, 7 and 9) supplemented with
1% (w/v) BSA. All the samples were analyzed by
HPLC and the collected fractions that contained in-
tact VIP were counted using a Cobra II Auto-Gamma
Counting System (Packard, USA). Concentrations
were calculated using a standard 10−8 M VIP solution
(containing 300,000 cpm/ml 125I-VIP) prepared at pH
4 with 1% (w/v) BSA just prior to analysis. A second
series of VIP stability experiments was also carried
out by checking the ability of 10−8 M unlabelled VIP
incubated in nasal wash solutions to inhibit 125I-VIP
binding in chicken liver membrane (see Section 2.6).
2.4.3. Evaluation of brain uptake after
intranasal perfusions
Perfusing solutions (1.5 ml) contained 10−8 M VIP,
125I-VIP (300,000 cpm/ml) and 1% (w/v) BSA and
were prepared (i) in 10 mM citrate (pH 4) or 10 mM
phosphate buffer (pH 7 or 9), (ii) without or with ab-
sorption enhancer (d,l-lauroylcarnitine chloride, 0.1%
or 1% w/v), (iii) in hypotonic (20 mOsm/kg) solution
or in solution made isotonic (300 mOsm/kg) by addi-
tion of sodium chloride. In order to minimize loss by
adsorption, tubing and containers used for nasal per-
fusion were previously pre-conditioned by circulating
similar solutions for 30 min before performing in vivo
experiments: conditioning was confirmed by determin-
ing VIP concentration by -counting. At the end of
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the intranasal perfusion, a blood sample was collected
by intracardiac puncture. A 300 ml volume of saline
(0.9% w/v sodium chloride) was then infused into the
aorta to remove blood from brain vessels. The skull
was opened and the brain collected and weighed. The
radioactivity was determined in brain and in blood by
-counting. Three rats were used per condition.
2.4.4. Qualitative analysis of brain or blood samples
by HPLC: comparison between intranasal and
intravenous administrations of VIP
A qualitative analysis of brain and blood sam-
ples was carried out by HPLC to check for the VIP
integrity after intranasal or intravenous routes. For in-
tranasal administration, the in situ nasal perfusion was
carried out for 30 min as described above, with a solu-
tion of VIP (10−8 M) and 125I-VIP (14×106 cpm/ml)
prepared in 0.01 M citrate buffer (pH 4) supple-
mented with 1% (w/v) BSA and with LC (0.1%
w/v). For the intravenous route, a solution of VIP
(3.6 × 10−10 M) and 125I-VIP (500,000 cpm/ml) in
saline supplemented with 1% (w/v) BSA was infused
for 30 min at a 4 ml/h flow rate, via an indwelling
jugular vein polyethylene cannula (i.d. 0.58 mm, o.d.
0.96 mm, Portex, France), with a PX 20B pump Ulis
(France). Brains, washed as described above, and
blood samples (600l) were homogenized on ice
with two volumes of 10 mM Tris buffer (pH 8) con-
taining protease inhibitors (1 mg/ml bacitracin, 1 mM
phenylmethylsulfonylfluoride, 0.2 mM antipain and
2 mM orthophenanthroline) using a Potter tissue ho-
mogenizer, and were centrifuged at 4 ◦C (1000 × g
for 10 min). Supernatants were collected and stored
on ice. The same extraction procedure was applied
two more times to the pellets. Finally, the three su-
pernatants collected for each sample were pooled and
ultracentrifuged at 100,000 × g for 30 min at 4 ◦C
using an Optima LE-80K ultracentrifuge (Beckman,
France) to spin down any remaining tissue debris.
The clear supernatant layers were collected and dried
under vacuum using a Speed-Vac (Heto Maxi Dry
Lyo FD1.0). Extracts were dissolved in 200l mobile
phase prior to HPLC analysis.
2.4.5. Brain distribution study after intranasal and
intravenous VIP administrations
Brain radioactivity distribution after intranasal
administration of 125I-VIP was studied by quanti-
tative autoradiographic analysis. A solution of VIP
(10−8 M) and 125I-VIP (300,000 cpm/ml) at pH 4 was
perfused intranasally for 30 min as described above.
After removing blood from brain vessels, brains were
fixed by infusing into the aorta 800 ml of a 4% (w/v)
paraformaldehyde solution in saline. Brains were se-
rially sectioned at 2 mm thickness. Sections were then
placed in a light-tight exposure cassette containing
a phosphor screen (Molecular Dynamics, Sunnyvale,
CA) for 3 weeks. Radioactivity signals were detected
by a Storm 820 imaging system (Molecular Dynam-
ics) using the ImageQuant software, and densito-
metric image analysis was carried out using a Scion
Image for Windows software (National Institutes of
Health, USA). Since the section thickness caused poor
anatomical details, fractional radioactivity per section
was presented here. Knowing the total amount of
radioactivity in the brain (determined by -counting)
and the weight of each section, the data were ex-
pressed as cpm per gram brain. Experiments were
triplicated and five quantifications were performed per
experiment. For brain radioactivity distribution after
intravenous route, a solution of VIP (3.6× 10−10 M)
and 125I-VIP (10,700 cpm/ml) in saline supplemented
with 1% (w/v) BSA was intravenously infused for
30 min as described above and radioactivity was di-
rectly determined by -counting in each brain section.
2.5. Reversed-phase HPLC analysis of VIP
VIP reversed-phase HPLC was carried out using a
5m VYDAC C18 column (Interchrom, France) with
-counting of 125I-VIP. A two-step linear gradient was
used with 0.1% (v/v) TFA in water as solvent A and
85:15 acetonitrile:0.1% (v/v) TFA in water as solvent
B. The column was equilibrated with solvent A at
a 1 ml/min flow-rate. Injection volume was 100l.
At each run, solvent B increased linearly from 0 to
35% in 2 min, then up to 100% in further 15 min, and
was maintained at 100% for another 5 min. Fractions
of 1 ml were collected and -counted. VIP eluted in
fractions 9–13 (see Fig. 1B).
2.6. Radioreceptor assay
Binding studies were performed on chicken liver
cell membranes as previously described (Meunier
et al., 1992). Briefly, cell membranes (100g),
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Fig. 1. Reversed-phase HPLC elution profiles of blood (A and C) or brain (B and D) extracts obtained after intranasal (i.n.) (A and B) or
intravenous (i.v.) (C and D) administrations of VIP, using 125I-VIP as a tracer (n = 3). 125I-VIP was evaluated by -counting. Intact VIP
eluted in fractions 9–13. For more details, see Section 2.
standard VIP solutions (or the VIP samples to be
tested) and 125I-VIP (30,000 cpm) were incubated at
room temperature and for 1 h in Dulbecco’s modified
Eagle’s medium containing 15 mM HEPES (pH 7.4),
1% (w/v) BSA, 0.1% (w/v) bacitracin and 150M
phenylmethylsulfonylfluoride (final volume: 400l).
After stopping the binding reaction by cooling on ice,
cell membranes were rinsed on Whatman GF/C filters
(Polylabo, France) with 8 ml of 150 mM Tris buffer
pH 7.5, containing 5 mM MgCl2, 0.1% (w/v) casein
and 0.5% (w/v) polyethyleneimine. The 125I-VIP still
bound to the membranes was -counted. The VIP
samples to be tested were evaluated by their ability
to inhibit the 125I-VIP binding, using a 10−7 M unla-
belled VIP as a 100%-inhibition control solution.
2.7. Statistical analysis
In vivo results were expressed as means ± S.E.M.
and statistical significance was determined by the
Student’s t-test to compare two groups or by one-way
analysis of variance (ANOVA) followed by the
Bonferroni’s multiple comparison test for more than
two groups. Differences were considered as signifi-
cant when P < 0.05. All in vivo experiments were
repeated three times (n).
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Table 1
Stability of VIP at 37 ◦C in buffers and in nasal wash solutions: effect of pH and lauroylcarnitine (LC)
pH VIP concentration (M) after incubation
Buffers Buffered nasal wash solution
Without LC With 0.1% LC (w/v)
4 1.00 × 10−8 0.88 × 10−8 (88%) 0.84 × 10−8 (84%)
7 0.90 × 10−8 0.69 × 10−8 (77%) 0.81 × 10−8 (90%)
9 0.71 × 10−8 0.59 × 10−8 (83%) 0.70 × 10−8 (100%)
VIP: initial concentration: 10−8 M.
Incubation time: 30 min.
VIP: concentrations were determined by HPLC using 125I-VIP as a tracer. Percentages within parentheses are calculated using VIP control
solutions as references. All the solutions contained 1% (w/v) BSA.
3. Results
3.1. Stability of VIP in nasal wash solutions
Stability studies of VIP in nasal wash solutions are
presented in Table 1. Controls incubated in buffers
showed no loss by adsorption onto the polyethylene
containers at pH 4, but noticeable loss at pH 7 and
9, despite the addition of BSA. In order to take into
account the (pH-dependent) adsorption phenomenon
in the calculation of VIP loss by mucosal metabolism,
results of VIP stability in nasal wash solutions were
also expressed as percentage of controls incubated
in buffer only. In all the conditions tested, VIP loss
(attributed to mucosal metabolism) was less than
23% over 30 min incubation, which was considered
as satisfactory. By radioreceptor assay, the 125I-VIP
displacement by VIP incubated with nasal wash solu-
tions was similar to a 10−8 M concentration of native
VIP (data not shown), indicating that the recovered
VIP identified by HPLC was also able to bind to
receptors.
3.2. In situ nasal perfusion experiments
The brain radioactivity uptake following intranasal
perfusions was dependent on the pH of the perfusing
solution: the highest uptake was observed at pH 9
(Table 2). Adding 0.1% LC to the perfusing solutions
increased significantly radioactivity levels in brain at
pH 4 or at pH 7 (the highest uptake being at pH 4), but
not at pH 9, resulting in similar radioactivity counts
for the three pH values tested (Table 2). More param-
eters were investigated at pH 4 (Table 3). Increasing
the LC concentration to 1% or the intranasal perfusion
time from 30 to 120 min did not alter brain uptake. The
addition of sodium chloride to make the perfusing so-
lution isoosmotic decreased the radioactivity levels in
brain, in comparison with results obtained without this
additive. As a general observation, the fraction of ra-
dioactivity recovered in brain was quite low compared
to the amount administered: with the most efficient
formulation (i.e. pH 4, 0.1% LC) the brain radioactiv-
ity levels after 30 min intranasal perfusion represented
only 0.11± 0.02% of the total radioactivity perfused
intranasally. In all the conditions tested, radioactivity
could be detected in blood (data not shown), indi-
cating a passage of VIP and/or of radioactive degra-
dation products from the nasal cavity into the blood
compartment.
Table 2
Effect of pH on VIP uptake estimated from brain radioactivity
measurements after intranasal administration
Brain uptake
(cpm/g ± S.E.M.)
pH 4 pH 7 pH 9
Without LC 65 ± 13a 68 ± 20b 153 ± 1
n.s. P < 0.05
P < 0.05
With LC 0.1% 217 ± 47a 154 ± 2b 148 ± 52
a,bSignificantly different (P < 0.05).
Intranasal perfusion time: 30 min.
Osmolality: 20 mOsm/kg.
Solutions: 10−8 M VIP/7.5×10−11 M 125I-VIP solutions, 1% (m/v)
BSA with or without 0.1% (m/v) lauroylcarnitine (LC) as perme-
ation enhancer.
Data represent the mean ± S.E.M. of three experiments.
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Table 3
Effect of some formulation parameters on VIP uptake after intranasal administration
Formulation parameters tested Brain uptake (cpm/g ± S.E.M.)
Lauroylcarnitine concentration (% w/v) Osmolality (mOsm/kg) Intranasal perfusion time (min)
0.1 20 30 217 ± 47a
0.1 20 120 130 ± 13b
0.1 300 30 44 ± 4c
1.0 20 30 118 ± 8d
Solution: 10−8 M VIP/7.5× 10−11 M 125I-VIP, 1% (w/v) BSA, pH 4.
Data represent the mean ± S.E.M. of three experiments. The superscript letters a, b, and d are not significantly different. The superscript
letters a and c are significantly different (P < 0.01); n = 3.
3.3. Qualitative analysis of brain or blood extracts
following intranasal or intravenous administrations
For both routes, radioactivity was detected in brains
and in blood samples (data not shown). HPLC analysis
of the blood extracts showed no peak corresponding
to intact VIP (Fig. 1A and C), by either administra-
tion routes. Analysis performed on the brain extracts
Fig. 2. Brain radioactivity distribution profiles after intranasal or intravenous (shown in the inset) administration of 125I-VIP. For intranasal
perfusion, radioactivity was evaluated by quantitative autoradiographic analysis of 2-mm thick brain slices. For intravenous infusion,
radioactivity was evaluated by -counting. The dotted lines on the rat brain representation (up left) denote the approximate spacing for
the cutting of the brain sections. For more details, see Section 2.
showed one peak corresponding to intact VIP, after in-
tranasal perfusions (fractions 9–13, Fig. 1B), but not
after intravenous infusions (Fig. 1D).
3.3.1. Brain distribution after nasal or
intravenous administration
Brain radioactivity distribution after intranasal per-
fusion or intravenous infusion is presented on Fig. 2.
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After intranasal perfusion, radioactivity was located in
section 1 corresponding to the cerebellum, in sections
4 (approximately between β − 5 and β − 6 mm) and
6 (approximately between β − 2.1 and β − 3.1 mm)
located in the midbrain, and in section 10 (approx-
imately between β + 2.7 and β + 1.7 mm) corre-
sponding to the olfactory bulbs and frontal cortex.
After intravenous administration, radioactivity was
homogeneously distributed in the whole brain.
4. Discussion
The VIP neuropeptide is unable to cross the BBB
and undergoes a rapid degradation in blood in vivo.
Therefore, the nasal route for administration was
investigated for its brain delivery. Preliminary ex-
periments were carried out to check for VIP loss by
adsorption on polyethylene containers or by mucosal
metabolism. In buffered solutions supplemented with
1% (w/v) BSA, VIP (10−8 M) adsorbed readily on
polyethylene containers at pH 9 and at 7, whereas no
loss occurred at pH 4 (Table 1). VIP is a polypeptide
characterized by a high pI of 9.82. As the adsorption
of polypeptides is maximum at pH values close to
the pI (Olivier et al., 1995), a pH above 7 should be
avoided to minimize loss. After 30 min incubation in
the presence of nasal wash solutions (with or without
LC), the loss of VIP attributed to mucosal metabolism
never exceeded 23% compared to control (Table 1).
Radioreceptor assay confirmed the ability of the
remaining VIP to interact with its receptors. VIP
stability in the presence of nasal secretions was there-
fore considered as satisfactory. Mucosal metabolism
should not be a barrier for VIP nasal absorption.
The in situ perfusion model of Hirai et al. (1981)
was applied to study the influence of formulation
parameters on the brain uptake of VIP administered
intranasally. This model provides accurate informa-
tion on basic parameters (pH, osmolality, use of per-
meation enhancers) that govern nasal drug absorption
(Olivier et al., 2001). In this model, drug concentration
is generally determined in the perfusing solution, in
order to quantify drug nasal absorption. In the case of
VIP, due to its low nasal absorption, the resulting de-
crease in VIP concentration in the perfusing solution
over 30 min was too low for an accurate evaluation
of VIP absorption. Therefore, only brain radioactivity
data were considered. In the absence of additive the
brain uptake of intranasally administered VIP was
pH-dependent, with the highest uptake obtained at pH
9 (Table 2). The transport of small drug molecules to
the cerebrospinal fluid from the nasal cavity was re-
ported to be dependent on their lipophilicity (Sakane
et al., 1991) and on their ionization state (Sakane
et al., 1994). VIP is a lipophilic peptide (Noda et al.,
1994), with a high pI (9.82). At a pH close to pI, VIP
possesses a neutral global electric charge, which may
facilitate its transmucosal absorption. The lower brain
uptakes observed at pH 4 or 7 were compensated by
the addition of LC (Table 2). With 0.1% (w/v) LC in
the formulation, the radioactivity levels in brain were
similar for the three pH values tested and close to the
maximum uptake obtained at pH 9 without additive.
At pH 4, a higher concentration of LC (1%) did not
increase further the brain uptake (Table 3). LC, an
endogenous amino acid-like surfactant, reportedly
enhanced nasal absorption of polypeptides, such as
azetirelin (Kagatani et al., 1998a) (tripeptide) and cal-
citonin (Kagatani et al., 1996) (32-amino acids), and
of proteins, such as human growth hormone (Kagatani
et al., 1998b) (191 amino acids), without inducing no-
ticeable toxicity to the nasal mucosa. Its maximum ef-
fect was observed at acidic pH and for a concentration
of 0.1% LC like in our experiments. The mechanism
underlying the effect of long-chain acylcarnitines was
studied on Caco-2 cells by Hochman et al. (1994) who
showed that palmitoylcarnitine micelles loosen epithe-
lial tight junctions, thus enhancing drug absorption.
The maximum effect observed at acidic pH is probably
due to the fact that the micelles formed by the zwitte-
rionic lauroylcarnitine (pK value of 4.85) at pH 4 are
cationic which may increase their interactions with the
negatively charged nasal epithelium (Kagatani et al.,
1996). Conversely, at pH 9, the negatively charged
zwitterion may have no or little interaction with the
negatively charged mucosa, thus explaining their in-
efficiency at promoting VIP absorption. The addition
of an osmotic agent (sodium chloride) to bring solu-
tions to isoosmolality had a negative effect on VIP
brain uptake (Table 3), probably because of a reduced
transmucosal absorption, as previously reported with
midazolam (Olivier et al., 2001) and with calcitonin
(Dua et al., 1997). In contrast, hypotonic solutions
cause cell swelling, which alters the epithelium para-
cellular permeability and helps for drug permeation
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through the mucosa (Pujara et al., 1995). Finally, a
120 min nasal perfusion time, in place of 30 min, did
not have any cumulative effect on the brain uptake.
Even in optimal conditions of nasal administration,
i.e. pH 4 and 0.1% lauroylcarnitine, the radioactivity
measured in brain was very low compared to the ra-
dioactivity levels applied intranasally: around 0.11%
of the total radioactivity present in the perfusing solu-
tions was detected in brain. This poor brain uptake was
in accordance with previous similar works carried out
with large polypeptides, such as insulin (Gizurarson
et al., 1997) or NGF (Frey et al., 1995). For neu-
ropeptides like VIP that are active at nanomolar, or
even femtomolar, concentrations, intranasal adminis-
trations are likely to give pharmacological responses,
as demonstrated for a VIP analogue (Gozes et al.,
1996).
After intranasal administration of 125I-VIP, ra-
dioactivity was also detected in blood, indicating that
a fraction of VIP (or VIP degradation product(s))
diffused from the nasal cavity into the blood compart-
ment. As shown by HPLC analysis of blood extract
(Fig. 1A), this fraction was not intact VIP. Hence,
in blood, radioactivity corresponded to 125I-VIP
degradation products only. The rapid and complete
degradation of VIP in the blood compartment was
in agreement with its very short VIP blood half-life
(Hassan et al., 1994) in vivo and was confirmed by
intravenous administration of VIP (Fig. 1C). In order
to check that the radioactivity detected in brain after
intranasal administration of 125I-VIP was actually
emitted by 125I-VIP, and not by its blood-borne degra-
dation products that could diffuse from the blood
compartment into the parenchyma through the BBB
or/and into BBB-lacking brain regions, like the cir-
cumventricular organs (Begley, 1996), brain samples
were also qualitatively analyzed by HPLC. As shown
in Fig. 1B, intranasally administered VIP (at least in
part) reached brain as intact molecules. As expected,
after intravenous infusion no intact VIP was found in
brain (Fig. 1D). These experiments definitely demon-
strated that the nasal route was effective to deliver
to brain a peptide that is almost instantaneously de-
graded in the blood compartment when administered
by intravenous route.
Quantitative autoradiographic analysis provided
additional information on the brain radioactivity dis-
tribution following intranasal 125I-VIP perfusion: the
radioactivity which corresponded, at least in part, to
125I-VIP was concentrated in specific brain sections
(Fig. 2). This distribution profile was very different
to the distribution profile obtained after intravenous
125I-VIP infusion: by IV, radioactivity, correspond-
ing to blood-borne 125I-VIP degradation products, as
shown by HPLC brain extract analysis (Fig. 1D), was
homogeneously distributed in the whole brain (Fig. 2,
inset). Interestingly, distribution after intranasal per-
fusion apparently corresponded to brain structures
known to be very rich in VIP receptors (Besson,
1988): cerebellum and pontine reticular nuclei (sec-
tion 1), the central grey, the geniculate, thalamic
and amygdaloid nuclei (section 4), the thalamic, hy-
pothalamic, amygdaloid nuclei, the primary olfactory
cortex and the caudate putamen (section 6), the ol-
factory bulbs, the olfactory tubercle and the frontal
cortex (section 10). It is unlikely that VIP reached all
these brain areas following the same pathway. Drugs
reach the olfactory bulbs by following the olfactory
nerve pathway (i.e. within olfactory receptor cells)
and/or the olfactory epithelial pathway (i.e. within the
perineural space) (Illum, 2000). However, the way
VIP reached specifically brain areas distant from the
nasal cavity (sections 1, 4 and 6) remains to be de-
termined. It is unlikely that VIP diffused through the
parenchyma from the anterior to the posterior brain
and specifically accumulated in brain structures rich
in VIP receptors, as intraparenchymal diffusion is
a very slow transfer process, very limited in extent
(generally a few millimeters), therefore not compati-
ble with the short duration of the intranasal infusions
(30 min) (Groothuis et al., 2000). Ceccatelli et al.
(1991) suggested that physiological VIP was locally
secreted by nerve fibers (e.g. of the local eminence)
into the brain portal circulation for brain blood flow
vascular regulation, thus implying that VIP could lo-
cally circulate in the blood compartment and interact
with receptors of the brain vessels. A local redistribu-
tion of intranasally administered VIP from the nasal
absorption site via the brain blood microcirculation
to BBB-lacking brain areas, like the circumventric-
ular organs (Begley, 1996), or to brain areas where
VIP vascular receptors are particularly rich could
therefore account for the observed brain distribution
profile. The very short VIP blood half-life and the
probably low amount of VIP involved in such path-
way might explain why 125I-VIP was not detected in
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peripheral blood by HPLC. This hypothesis needs to
be experimentally confirmed.
In conclusion, the hypotonic formulation of VIP
at pH 4 with 0.1% d,l-lauroylcarnitine and 1%
BSA minimized VIP adsorption onto polyethylene
tubes and permitted VIP brain delivery via the direct
nose-to-brain pathway. Even if not completely satis-
factory from a pharmaceutical view point due to the
low brain uptake obtained, the nasal route for admin-
istration offers particularly interesting perspectives
for the in vivo evaluation of the action of peptides on
the CNS that cannot be administered intravenously,
either because they cannot cross the BBB or because
they are rapidly degraded in the blood compartment.
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